A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH). In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. This causes high blood pressure in the lungs and can overwork the heart. PAH can make it hard to breathe and be active. Researchers want to learn if sotatercept, the study medicine, can be given with standard treatment to help treat PAH. The…
Conditions studied
Pulmonary Arterial Hypertension
About this study
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH). In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. This causes high blood pressure in the lungs and can overwork the heart. PAH can make it hard to breathe and be active. Researchers want to learn if sotatercept, the study medicine, can be given with standard treatment to help treat PAH. The standard treatment (the usual treatment) for PAH includes one or multiple medicines. However, these may not fully work or treat the symptoms of PAH in some people. The goal of this study is to learn about the safety and tolerability of sotatercept when it is given with standard treatment to people in India.
Interventions
- Biological: Sotatercept — Administered as SC injection
- Drug: Background PAH Therapy — Background PAH therapy refers to approved PAH-specific medications and may consist of a single, double, or triple combination of therapy with Endothelin Receptor Antagonists (ERAs), Phosphodiesterase Type 5 Inhibitors (PDE5), soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists
Primary outcomes
- Number of participants who experience an adverse event (AE) (Up to approximately 37 weeks)
- Number of participants who discontinue study intervention due to an AE (Up to approximately 21 weeks)
Eligibility information
Study locations
- Renova Century Hospitals ( Site 0011), Hyderabad, Andhra Pradesh 500028 India
- KLES Dr. Prabhakar Kore Hospital & M.R.C ( Site 0013), Belagavi, Karnataka 590010 India
- Madras Medical Mission Hospital ( Site 0008), Chennai, Tamil Nadu 600037 India
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-18.